AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of “Moderate Buy” by Brokerages

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have been assigned an average rating of “Moderate Buy” from the twelve analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $82.00.

Several research analysts recently commented on ANAB shares. Barclays increased their price target on AnaptysBio from $63.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. Wall Street Zen cut shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Zacks Research cut AnaptysBio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 2nd. Piper Sandler lowered their price target on AnaptysBio from $95.00 to $93.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. Finally, Weiss Ratings lowered AnaptysBio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th.

Institutional Investors Weigh In On AnaptysBio

Large investors have recently added to or reduced their stakes in the business. Persistent Asset Partners Ltd bought a new position in AnaptysBio during the second quarter worth $39,000. Smartleaf Asset Management LLC raised its position in shares of AnaptysBio by 5,864.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 821 shares during the period. Larson Financial Group LLC raised its position in shares of AnaptysBio by 54.6% in the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 473 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of AnaptysBio by 175.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after buying an additional 1,377 shares during the last quarter. Finally, Osaic Holdings Inc. lifted its stake in shares of AnaptysBio by 11,630.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after buying an additional 2,326 shares during the last quarter.

AnaptysBio Stock Performance

Shares of ANAB stock opened at $56.61 on Tuesday. The company has a market capitalization of $1.68 billion, a P/E ratio of -52.42 and a beta of 0.72. The company’s 50 day moving average price is $57.48 and its two-hundred day moving average price is $58.04. AnaptysBio has a 52 week low of $11.40 and a 52 week high of $72.36.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($1.20). The firm had revenue of $25.56 million for the quarter, compared to the consensus estimate of $18.86 million. Analysts forecast that AnaptysBio will post -1.35 earnings per share for the current year.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.